Chromadex Corp Company Profile (OTCMKTS:CDXC)

About Chromadex Corp (OTCMKTS:CDXC)

Chromadex Corp logoChromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:CDXC
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $125.34 million
  • Outstanding Shares: 39,790,000
Average Prices:
  • 50 Day Moving Avg: $2.94
  • 200 Day Moving Avg: $2.80
  • 52 Week Range: $2.25 - $5.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 8.75
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $23.93 million
  • Price / Sales: 5.24
  • Book Value: $0.25 per share
  • Price / Book: 12.60
Profitability:
  • EBIDTA: ($4,020,000.00)
Misc:
  • Average Volume: 339,018 shs.
  • Short Ratio: 12.13
 

Frequently Asked Questions for Chromadex Corp (OTCMKTS:CDXC)

What is Chromadex Corp's stock symbol?

Chromadex Corp trades on the OTCMKTS under the ticker symbol "CDXC."

How were Chromadex Corp's earnings last quarter?

Chromadex Corp (OTCMKTS:CDXC) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.05. The business earned $5.64 million during the quarter, compared to analysts' expectations of $5.60 million. View Chromadex Corp's Earnings History.

Where is Chromadex Corp's stock going? Where will Chromadex Corp's stock price be in 2017?

2 brokers have issued 12 month price targets for Chromadex Corp's shares. Their forecasts range from $6.00 to $6.00. On average, they expect Chromadex Corp's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Chromadex Corp.

Who are some of Chromadex Corp's key competitors?

Who owns Chromadex Corp stock?

Chromadex Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Tieton Capital Management LLC (0.00%), Granite Investment Partners LLC (0.65%), Geode Capital Management LLC (0.00%), North Star Investment Management Corp. (0.39%) and TIAA CREF Investment Management LLC (0.00%). Company insiders that own Chromadex Corp stock include Frank L Jaksch Jr, Robert N Fried, Stephen R Allen and Troy Allen Rhonemus. View Institutional Ownership Trends for Chromadex Corp.

Who sold Chromadex Corp stock? Who is selling Chromadex Corp stock?

Chromadex Corp's stock was sold by a variety of institutional investors in the last quarter, including North Star Investment Management Corp., Morgan Stanley, Granite Investment Partners LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Chromadex Corp.

Who bought Chromadex Corp stock? Who is buying Chromadex Corp stock?

Chromadex Corp's stock was purchased by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Vanguard Group Inc., Teachers Advisors LLC, Geode Capital Management LLC and Segall Bryant & Hamill LLC. Company insiders that have bought Chromadex Corp stock in the last two years include Frank L Jaksch Jr, Robert N Fried, Stephen R Allen and Troy Allen Rhonemus. View Insider Buying and Selling for Chromadex Corp.

How do I buy Chromadex Corp stock?

Shares of Chromadex Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Chromadex Corp stock cost?

One share of Chromadex Corp stock can currently be purchased for approximately $3.15.

Analyst Ratings

Consensus Ratings for Chromadex Corp (OTCMKTS:CDXC) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00

Analysts' Ratings History for Chromadex Corp (OTCMKTS:CDXC)
Show:
DateFirmActionRatingPrice TargetDetails
3/20/2017HC WainwrightSet Price TargetBuy$6.00View Rating Details
1/3/2017Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Chromadex Corp (OTCMKTS:CDXC)
Earnings by Quarter for Chromadex Corp (OTCMKTS:CDXC)
Earnings History by Quarter for Chromadex Corp (OTCMKTS:CDXC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2017Q4 2016($0.01)($0.06)$5.60 million$5.64 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.03)$5.01 millionViewListenView Earnings Details
8/11/2016Q216$0.01$6.10 million$8.80 millionViewListenView Earnings Details
5/12/2016Q116$0.01$5.30 million$7.30 millionViewListenView Earnings Details
11/21/2013Q3 13($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Chromadex Corp (OTCMKTS:CDXC)
Current Year EPS Consensus Estimate: $0.16 EPS
Next Year EPS Consensus Estimate: $0.36 EPS

Dividends

Dividend History for Chromadex Corp (OTCMKTS:CDXC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Chromadex Corp (OTCMKTS:CDXC)
Insider Trades by Quarter for Chromadex Corp (OTCMKTS:CDXC)
Institutional Ownership by Quarter for Chromadex Corp (OTCMKTS:CDXC)
Insider Trades by Quarter for Chromadex Corp (OTCMKTS:CDXC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2017Stephen R AllenDirectorBuy3,000$3.20$9,600.00View SEC Filing  
3/20/2017Stephen R AllenDirectorBuy2,000$2.81$5,620.00View SEC Filing  
12/12/2016Frank L Jaksch JrCEOBuy2,000$2.42$4,840.00View SEC Filing  
9/1/2016Frank L Jaksch JrCEOBuy1,500$3.32$4,980.00View SEC Filing  
9/1/2016Robert N FriedDirectorBuy15,000$3.39$50,850.00View SEC Filing  
6/20/2016Troy Allen RhonemusCOOBuy7,800$3.47$27,066.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Chromadex Corp (OTCMKTS:CDXC)
Latest Headlines for Chromadex Corp (OTCMKTS:CDXC)
Source:
DateHeadline
seekingalpha.com logoChromaDex's (CDXC) CEO Frank Jaksch on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 9:47 PM
finance.yahoo.com logoChromaDex reports 1Q loss
finance.yahoo.com - May 11 at 9:52 PM
finance.yahoo.com logoInvestor Network: ChromaDex Corporation to Host Earnings Call
finance.yahoo.com - May 11 at 4:48 PM
finance.yahoo.com logoChromaDex Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 4:48 PM
finance.yahoo.com logoChromaDex to Report First Quarter 2017 Financial Results on Thursday, May 11, 2017
finance.yahoo.com - May 4 at 4:22 PM
finance.yahoo.com logoETFs with exposure to Chromadex Corp. : April 24, 2017
finance.yahoo.com - April 24 at 4:08 PM
finance.yahoo.com logoChromaDex to Showcase Novel Ingredient Science and Brand-Elevating Services at Ingredient Marketplace 2017
finance.yahoo.com - April 11 at 10:35 AM
finance.yahoo.com logoChromaDex to Present at the Cowen and Company’s 3rd Annual Future of the Consumer Conference: Convergence & Disruption on April 4, 2017
finance.yahoo.com - March 29 at 12:21 PM
streetinsider.com logoChromaDex (CDXC) Appoints Steven Rubin to its Board of Directors - StreetInsider.com
www.streetinsider.com - March 28 at 4:02 PM
streetinsider.com logoChromaDex (CDXC) Appoints Steven Rubin to its Board of Directors
www.streetinsider.com - March 28 at 12:46 PM
americanbankingnews.com logoHC Wainwright Analysts Give Chromadex Corp (CDXC) a $6.00 Price Target
www.americanbankingnews.com - March 21 at 3:40 PM
finance.yahoo.com logoEdited Transcript of CDXC earnings conference call or presentation 17-Mar-17 5:00pm GMT
finance.yahoo.com - March 20 at 7:32 PM
americanbankingnews.com logoZacks Investment Research Lowers Chromadex Corp (CDXC) to Sell
www.americanbankingnews.com - March 20 at 5:37 PM
seekingalpha.com logoChromaDex's (CDXC) CEO Frank Jaksch on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 17 at 9:50 PM
nasdaq.com logoChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34%
www.nasdaq.com - March 16 at 5:33 PM
biz.yahoo.com logoQ4 2016 Chromadex Corp Earnings Release - After Market Close
us.rd.yahoo.com - March 16 at 5:33 PM
americanbankingnews.com logoChromadex Corp (CDXC) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:06 AM
finance.yahoo.com logoChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017
finance.yahoo.com - March 10 at 5:12 PM
us.rd.yahoo.com logoA Letter from the ChromaDex Chief Executive Officer
us.rd.yahoo.com - February 23 at 4:11 PM
streetinsider.com logoChromaDex (CDXC) Says Study Published in PAIN Shows Nicotinamide Riboside is Effective Tool in Relieving Chemotherapy-Induced Peripheral Neuropathy
www.streetinsider.com - February 23 at 2:22 AM
streetinsider.com logoChromaDex (CDXC) Says Study Published in PAIN Shows Nicotinamide Riboside is Effective Tool in Relieving ... - StreetInsider.com
www.streetinsider.com - February 22 at 9:20 PM
finance.yahoo.com logoStudy Published in PAIN Reveals Nicotinamide Riboside is an Effective Tool in Relieving Chemotherapy-Induced Peripheral Neuropathy Induced by a Common Anticancer Agent
finance.yahoo.com - February 22 at 12:11 PM
finance.yahoo.com logo6:31 am ChromaDex announces the publication of a study by U of Iowa researchers in the Journal of the International Association for the Study of Pain showing that NIAGEN Nicotinamide Riboside ameliorates chemotherapy-induced peripheral neur
finance.yahoo.com - February 22 at 12:11 PM
finance.yahoo.com logoChromaDex to Showcase Premier Innovation and Brand-Elevating Science at Engredea 2017
finance.yahoo.com - February 21 at 2:26 PM
biz.yahoo.com logoCHROMADEX CORP. Files SEC form 8-K, Other Events
biz.yahoo.com - February 17 at 6:00 PM
streetinsider.com logoChromaDex (CDXC) Sees Q4 Revenue of $5.6M - StreetInsider.com
www.streetinsider.com - February 16 at 9:02 AM
finance.yahoo.com logoChromaDex Expects to Report Record Fourth Quarter as Revenue Increased Approximately 29%
finance.yahoo.com - February 14 at 4:56 PM
biz.yahoo.com logoCHROMADEX CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - February 14 at 4:56 PM
biz.yahoo.com logoCHROMADEX CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 9:41 PM
finance.yahoo.com logoChromaDex to Present at the ICR Conference 2017 on January 11, 2017
finance.yahoo.com - January 4 at 5:15 PM

Social

Chart

Chromadex Corp (CDXC) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff